Natera: How the Diagnostics Pioneer is Redefining the Cancer Market with Cell-Free DNA

Natera has a proprietary cfDNA platform that enables non-invasive, highly accurate diagnostic tests in key areas such as women's health, oncology, and organ health. The main driver for future revenue growth is the personalized cancer test Signatera, which is positioning itself as the new standard for monitoring minimal residual disease (MRD) in the billion-dollar cancer follow-up market. The company is demonstrating very strong revenue growth but is still heavily investing in research and sales to gain market share. Profitability is currently...